361 Capital’s Palvella Therapeutics PVLA Stock Holding History

361 Capital’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,777	Closed	-$1.51M	–	413
2018 Q1	$1.51M	Buy	+2,777	New	+$1.72M	0.38%	113

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

361 Capital's PVLA Position: Q2 2018 in Review

361 Capital sold out of Palvella Therapeutics (PVLA) in Q2 2018, closing a stake of 2,777 shares — an estimated $1.51M sold.

361 Capital first reported a position in PVLA in Q1 2018 and held it in 1 quarter. The position peaked at $1.51M in Q1 2018. 115 funds tracked by Wall St. Rank hold PVLA as of Q2 2018.

361 Capital reported no remaining Palvella Therapeutics position as of Q2 2018 after selling out during the quarter.
361 Capital sold 2,777 Palvella Therapeutics shares in Q2 2018, an estimated $1.51M.
361 Capital first reported a position in Palvella Therapeutics in Q1 2018 and held it in 1 quarter.
361 Capital's Palvella Therapeutics position peaked at $1.51M in Q1 2018.
115 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2018.

Based on 361 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.